Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-1.04 Insider Own1.10% Shs Outstand90.33M Perf Week11.84%
Market Cap4.09B Forward P/E- EPS next Y-0.09 Insider Trans-41.54% Shs Float74.14M Perf Month26.92%
Income-93.70M PEG- EPS next Q-0.13 Inst Own68.60% Short Float4.03% Perf Quarter2.61%
Sales232.10M P/S17.61 EPS this Y29.30% Inst Trans1.38% Short Ratio3.60 Perf Half Y27.13%
Book/sh1.24 P/B36.50 EPS next Y86.40% ROA-19.70% Target Price45.25 Perf Year113.49%
Cash/sh2.52 P/C17.95 EPS next 5Y60.00% ROE-52.70% 52W Range19.06 - 53.70 Perf YTD35.19%
Dividend- P/FCF- EPS past 5Y- ROI-41.40% 52W High-15.72% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin68.70% 52W Low137.52% ATR1.97
Employees495 Current Ratio6.20 Sales Q/Q29.30% Oper. Margin-12.70% RSI (14)77.15 Volatility4.46% 6.00%
OptionableYes Debt/Eq1.30 EPS Q/Q2.40% Profit Margin-25.40% Rel Volume1.36 Prev Close44.50
ShortableYes LT Debt/Eq1.30 EarningsJan 24 BMO Payout- Avg Volume829.72K Price45.26
Recom2.00 SMA2028.47% SMA5034.34% SMA20029.78% Volume1,127,107 Change1.71%
Nov-02-18Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18Initiated Evercore ISI Outperform $46
Apr-18-18Reiterated Mizuho Buy $28 → $32
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-27-15Initiated Wedbush Outperform
Oct-27-15Initiated JP Morgan Overweight
Oct-27-15Initiated JMP Securities Mkt Outperform $43
Jan-11-19 12:24PM  Tamarack Capital Managements Return, AUM, and Holdings Insider Monkey
Jan-07-19 04:05PM  Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update Business Wire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-24-18 09:44AM  Is NovoCure a Buy? Motley Fool
Dec-21-18 07:30AM  Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-17-18 02:20PM  What Kind Of Shareholder Owns Most NovoCure Limited (NASDAQ:NVCR) Stock? Simply Wall St.
07:30AM  Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields Business Wire
Dec-16-18 09:10AM  Is NovoCure Limited (NVCR) A Good Stock To Buy? Insider Monkey
Dec-12-18 11:49AM  3 Top Medical Device Stocks to Buy Now Motley Fool
Dec-07-18 07:55AM  Recent Analysis Shows Moody's, Hershey, NovoCure, Mohawk Industries, La-Z-Boy, and Lockheed Martin Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Dec-06-18 07:30AM  Sub-Group Analysis of Novocures EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival Business Wire
Nov-14-18 07:30AM  Zai Lab and Novocure Awarded Deal of the Year GlobeNewswire
07:30AM  Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China Business Wire
Nov-13-18 08:01PM  3 Top Healthcare Stocks to Buy in November Motley Fool
08:24AM  Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-07-18 04:00PM  Novocure and Zai Lab to Host Investor Event Business Wire +8.33%
12:25PM  NovoCure Limited (NASDAQ:NVCR): Is Breakeven Near? Simply Wall St.
11:22AM  Here's Why NovoCure Fell 36.8% in October Motley Fool
Oct-30-18 02:04PM  Edited Transcript of NVCR earnings conference call or presentation 25-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
07:30AM  New Research Coverage Highlights HomeStreet, Cousins Properties, Carbo Ceramics, Cowen Group, CTS, and NovoCure Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-25-18 03:11PM  Here's Why Novocure Is Tumbling Today Motley Fool -18.98%
09:05AM  NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:00AM  Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update Business Wire
Oct-24-18 04:00PM  Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors Business Wire
Oct-23-18 05:57PM  Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma Business Wire
Oct-22-18 07:30AM  Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields Business Wire
Oct-18-18 10:33AM  NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For Zacks
07:30AM  Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune® Business Wire
Oct-11-18 08:03AM  Why Novocure Stock Jumped 16.3% in September Motley Fool
Oct-04-18 09:08AM  Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018 Business Wire
Oct-02-18 11:51AM  3 Medical Devices Stocks to Buy InvestorPlace
Oct-01-18 08:36AM  Novocure to Report Third Quarter 2018 Financial Results Business Wire
Sep-25-18 07:30AM  Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer Business Wire
Sep-14-18 03:04PM  What Investors Should Know About NovoCure Limiteds (NASDAQ:NVCR) Financial Strength Simply Wall St.
Sep-13-18 10:57AM  5 Medical Device Stocks With Impressive Staying Power InvestorPlace
Sep-12-18 07:30AM  Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Business Wire
Sep-10-18 10:31AM  Why Novocure Gained 33% in August Motley Fool
Sep-06-18 11:24AM  Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles Investing.com +5.34%
08:00AM  Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure ACCESSWIRE
Sep-05-18 05:00PM  Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control Business Wire
Aug-31-18 04:38PM  This brain cancer drug stock has been on a tear Yahoo Finance
Aug-26-18 07:15PM  3 Small-Cap Healthcare Stocks for Your Watch List Motley Fool
Aug-24-18 08:00AM  Today's Research Reports on Trending Tickers: Exact Sciences and NovoCure ACCESSWIRE
Aug-23-18 07:55AM  Research Report Identifies Genesis Healthcare, Maiden, Ichor, Armstrong World Industries, Rexnord, and NovoCure with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-17-18 07:30AM  This $7 Biotech Stock Could Be Worth $20 or More After Recent Developments ACCESSWIRE
Aug-15-18 08:38AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:30AM  Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer Business Wire
Aug-06-18 12:18PM  Forget Bitcoin: You're Better Off Buying These 3 Stocks Motley Fool
Aug-03-18 07:30AM  Novocure to Present at Two Upcoming Investor Conferences Business Wire
Aug-02-18 07:30AM  Novocure Announces Addition to Its Board of Directors Business Wire
Jul-31-18 07:30AM  Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer Business Wire
Jul-26-18 07:19PM  Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
06:00AM  Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update Business Wire
Jul-19-18 07:30AM  Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting Business Wire
Jul-17-18 08:54AM  NovoCure (NVCR) Catches Eye: Stock Jumps 7.4% Zacks
07:30AM  Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society Business Wire
Jul-16-18 07:05AM  Free Pre-Market Technical Recap on Nevro and Three Additional Medical Equipment Stocks ACCESSWIRE +7.40%
Jul-14-18 03:35PM  Here's Why Novocure Ltd. Rose 55% in the First Half of 2018 Motley Fool
Jul-06-18 09:13AM  Trade of the Day: Novocure Ltd (NVCR) InvestorPlace
Jul-02-18 08:00AM  Novocure Appoints Pritesh Shah as Chief Commercial Officer Business Wire
07:30AM  Novocure to Report Second Quarter 2018 Financial Results Business Wire
Jun-21-18 02:40PM  NovoCure's Charts Look Bullish TheStreet.com
Jun-20-18 07:01PM  Cramer's lightning round: The pecking order for my favori... CNBC Videos
06:49PM  Cramer's lightning round: The pecking order for my favorite cybersecurity stocks CNBC
Jun-15-18 08:10AM  Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-04-18 10:37AM  The Probable Reason Behind NovoCure's Double-Digit Drop Today Motley Fool -7.51%
07:30AM  Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 Business Wire
May-31-18 04:05PM  Novocure Announces Changes to Its Board of Directors Business Wire
07:20AM  Breakfast Technical Briefing on NovoCure and Three Other Additional Medical Equipment Stocks ACCESSWIRE
May-14-18 12:02PM  Best Growth Stock in May Simply Wall St.
May-11-18 11:46AM  Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-18 04:53PM  This Explains Why NovoCure Is Surging Today Motley Fool +9.73%
11:55AM  NovoCure: 1Q Earnings Snapshot Associated Press
06:00AM  Novocure Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Apr-25-18 11:10AM  NovoCure (NVCR) Shares March Higher, Can It Continue Zacks
Apr-19-18 08:00AM  Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.04%
07:10AM  Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma ACCESSWIRE
Apr-18-18 08:31AM  NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session Zacks
Apr-17-18 07:30AM  Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Business Wire +7.89%
Apr-13-18 06:31PM  3 Top Healthcare Stocks to Buy in April Motley Fool
04:30PM  Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting Business Wire
Apr-03-18 12:23PM  Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet A Threat To Its Future? Simply Wall St.
07:30AM  Novocure to Report First Quarter 2018 Financial Results Business Wire
Mar-20-18 09:14AM  NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma Business Wire
Mar-19-18 07:00AM  Wired News NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018 ACCESSWIRE
Mar-15-18 05:42PM  Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR) Simply Wall St.
07:30AM  Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 Business Wire
Mar-08-18 04:21PM  Edited Transcript of NVCR earnings conference call or presentation 22-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Feb-26-18 07:03PM  Cramer Remix: It's time to investigate risky VIX-related ... CNBC Videos +7.25%
07:02PM  Tumor-treating biotech Novocure turns its attention to lu... CNBC Videos
06:59PM  Cramer Remix: It's time to investigate risky VIX-related trading products CNBC
Feb-22-18 07:30AM  NovoCure reports 4Q loss Associated Press
06:00AM  Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Feb-13-18 05:19PM  Who Really Owns NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
Feb-09-18 07:55AM  Report: Exploring Fundamental Drivers Behind Vector Group, NovoCure, ORBCOMM, Adamis Pharmaceuticals, Calumet Specialty Products Partners, and Lakeland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-18 04:01PM  Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Business Wire
Feb-05-18 08:31AM  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
Feb-01-18 11:05AM  JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients Business Wire
Markets a wearable electric field device for treating glioblastoma brain cancer.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Danziger AsafChief Executive OfficerJan 15Option Exercise3.44100,000344,000271,164Jan 16 04:31 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 15Option Exercise3.4430,000103,20067,149Jan 16 04:32 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 15Sale44.2030,0001,326,00037,149Jan 16 04:32 PM
Danziger AsafChief Executive OfficerJan 15Sale43.49100,0004,348,800171,164Jan 16 04:31 PM
Danziger AsafChief Executive OfficerJan 14Option Exercise3.44100,000344,000271,164Jan 16 04:31 PM
Danziger AsafChief Executive OfficerJan 14Sale43.52100,0004,352,400171,164Jan 16 04:31 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 11Option Exercise3.4430,000103,20067,149Jan 14 04:30 PM
Shah PriteshChief Commercial OfficerJan 11Option Exercise12.4326,251326,30234,587Jan 14 04:35 PM
Shah PriteshChief Commercial OfficerJan 11Sale42.0026,2511,102,64717,087Jan 14 04:35 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 11Sale42.3530,0001,270,50037,149Jan 14 04:30 PM
LEUNG GABRIELDirectorJan 10Option Exercise3.445,00017,20065,000Jan 14 04:32 PM
Ambrogi Michael J.Chief Operating OfficerJan 10Option Exercise14.3754,930789,344201,488Jan 14 04:34 PM
Ambrogi Michael J.Chief Operating OfficerJan 10Sale40.8854,9302,245,810146,558Jan 14 04:34 PM
LEUNG GABRIELDirectorJan 10Sale39.915,000199,55060,000Jan 14 04:32 PM
Shah PriteshChief Commercial OfficerJan 09Option Exercise14.378,988129,15826,075Jan 11 04:16 PM
Ambrogi Michael J.Chief Operating OfficerJan 09Option Exercise13.64100,0001,364,250221,558Jan 11 04:18 PM
Longsworth Todd ChristopherGeneral CounselJan 09Option Exercise7.1515,000107,25036,305Jan 11 04:21 PM
LEUNG GABRIELDirectorJan 09Option Exercise3.4420,00068,80080,000Jan 11 04:23 PM
LEUNG GABRIELDirectorJan 09Sale40.0020,000800,06760,000Jan 11 04:23 PM
Longsworth Todd ChristopherGeneral CounselJan 09Sale40.1515,000602,25021,305Jan 11 04:21 PM
Ambrogi Michael J.Chief Operating OfficerJan 09Sale40.00100,0004,000,000146,558Jan 11 04:18 PM
Shah PriteshChief Commercial OfficerJan 09Sale40.008,988359,55017,087Jan 11 04:16 PM
Shah PriteshChief Commercial OfficerDec 12Option Exercise7.3438,781284,72039,619Dec 13 05:27 PM
Shah PriteshChief Commercial OfficerDec 12Sale36.0038,7811,396,13617,087Dec 13 05:27 PM
LEUNG GABRIELDirectorDec 10Option Exercise3.445,00017,20065,000Dec 12 04:26 PM
LEUNG GABRIELDirectorDec 10Sale33.495,000167,45060,000Dec 12 04:26 PM
Palti YoramChief Technology OfficerAug 28Sale40.274,334174,5491,041,054Aug 30 04:09 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 27Sale40.039,973399,20337,124Aug 28 04:24 PM
Palti YoramChief Technology OfficerAug 27Sale40.0513,450538,6631,045,388Aug 28 04:22 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 24Sale40.0025,5741,022,97047,097Aug 28 04:24 PM
Palti YoramChief Technology OfficerAug 24Sale40.0012,216488,6451,058,838Aug 28 04:22 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 22Sale37.6731,1791,174,60372,671Aug 24 04:05 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 14Sale37.624,368164,345103,850Aug 16 04:30 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 02Sale35.017,126249,500108,218Aug 06 04:15 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerAug 01Sale35.011,24143,445115,344Aug 02 04:13 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJul 27Sale35.0862,7272,200,335116,585Jul 30 04:39 PM
DOYLE WILLIAM FExecutive ChairmanJul 16Option Exercise3.592,3308,365914,473Jul 18 04:54 PM
Ambrogi Michael J.Chief Operating OfficerJul 02Option Exercise7.2657,390416,756203,948Jul 05 04:08 PM
Ambrogi Michael J.Chief Operating OfficerJul 02Sale31.4857,3901,806,637146,558Jul 05 04:08 PM
Danziger AsafChief Executive OfficerJun 27Sale32.0970,3642,257,69969,318Jun 29 04:05 PM
Danziger AsafChief Executive OfficerJun 20Sale32.048,308266,148139,682Jun 21 04:16 PM
Danziger AsafChief Executive OfficerJun 19Sale32.0062119,872147,990Jun 21 04:16 PM
Danziger AsafChief Executive OfficerJun 18Sale32.0022,289713,248148,611Jun 19 04:14 PM
Palti YoramChief Technology OfficerJun 15Sale31.0930,000932,8021,101,054Jun 19 04:12 PM
Palti YoramChief Technology OfficerJun 14Sale31.6430,000949,2691,131,054Jun 15 04:23 PM
Danziger AsafChief Executive OfficerJun 14Sale32.002006,400170,900Jun 15 04:22 PM
Kirson Eilon D.Chief Science OfficerJun 13Option Exercise12.7768,250871,628107,832Jun 15 04:24 PM
Danziger AsafChief Executive OfficerJun 13Sale32.0011,720375,040171,100Jun 15 04:22 PM
Kirson Eilon D.Chief Science OfficerJun 04Option Exercise7.13346,1612,468,310258,363Jun 06 05:28 PM
Danziger AsafChief Executive OfficerJun 04Sale29.09227,3046,612,801182,820Jun 06 08:12 PM
Kirson Eilon D.Chief Science OfficerJun 04Sale28.90346,16110,003,51433,067Jun 06 05:28 PM
PHILLIPS CHARLES G IIIDirectorMay 25Option Exercise6.7250,000336,00050,000May 30 06:01 PM
PHILLIPS CHARLES G IIIDirectorMay 25Sale30.3050,0001,515,0750May 30 06:01 PM
LEUNG GABRIELDirectorMay 16Option Exercise3.44100,000344,000100,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 16Sale28.7740,0001,150,80060,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 15Option Exercise3.4440,000137,60040,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 15Sale28.8840,0001,155,2000May 17 04:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 14Sale30.0521,077633,411178,121May 15 04:26 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 11Sale30.019,393281,858199,198May 15 04:26 PM
Ambrogi Michael J.Chief Operating OfficerMay 01Option Exercise3.4428,69598,711175,253May 03 04:34 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 01Sale27.5830,470840,363208,591May 03 04:30 PM
Ambrogi Michael J.Chief Operating OfficerMay 01Sale27.4060,0001,644,000146,558May 03 04:34 PM
Ambrogi Michael J.Chief Operating OfficerApr 26Option Exercise3.4420,00068,800166,558Apr 30 05:56 PM
Ambrogi Michael J.Chief Operating OfficerApr 26Sale26.0120,000520,142146,558Apr 30 05:56 PM
Palti YoramChief Technology OfficerApr 26Sale26.0920,966547,0131,161,054Apr 30 05:03 PM
Palti YoramChief Technology OfficerApr 24Sale25.065,600140,3201,182,020Apr 25 04:08 PM
Palti YoramChief Technology OfficerApr 23Sale25.0730,000751,9621,187,620Apr 25 04:08 PM
Palti YoramChief Technology OfficerApr 20Sale25.0619,362485,1831,217,620Apr 23 04:05 PM
Palti YoramChief Technology OfficerApr 19Sale24.9330,000748,0421,236,982Apr 23 04:05 PM
Ambrogi Michael J.Chief Operating OfficerApr 18Option Exercise3.4420,00068,800166,558Apr 19 04:54 PM
Kirson Eilon D.Chief Science OfficerApr 18Option Exercise3.44147,825508,518116,451Apr 20 04:53 PM
Kirson Eilon D.Chief Science OfficerApr 18Sale24.00147,8253,547,80039,582Apr 20 04:53 PM
Ambrogi Michael J.Chief Operating OfficerApr 18Sale24.0020,000480,000146,558Apr 19 04:54 PM
Palti YoramChief Technology OfficerApr 18Sale24.1014,072339,0801,266,982Apr 19 04:21 PM
Ambrogi Michael J.Chief Operating OfficerApr 17Option Exercise3.4420,00068,800166,558Apr 19 04:54 PM
Ambrogi Michael J.Chief Operating OfficerApr 17Sale22.0620,000441,240146,558Apr 19 04:54 PM
Palti YoramChief Technology OfficerApr 17Sale23.4430,000703,2241,281,054Apr 19 04:21 PM
Palti YoramChief Technology OfficerApr 04Sale19.8930,000596,7541,311,054Apr 05 04:17 PM
Palti YoramChief Technology OfficerApr 03Sale20.1930,000605,5681,341,054Apr 04 04:05 PM
Palti YoramChief Technology OfficerApr 02Sale20.4630,000613,8611,371,054Apr 04 04:05 PM
Palti YoramChief Technology OfficerMar 29Sale21.6730,000649,9771,401,054Apr 02 04:05 PM
Ambrogi Michael J.Chief Operating OfficerMar 19Option Exercise0.2349,72811,437146,558Mar 20 04:37 PM
Longsworth Todd ChristopherGeneral CounselFeb 23Sale19.836,591130,68620,074Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 23Sale19.838,458167,70596,830Feb 26 05:13 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 23Sale19.8313,351264,724239,061Feb 26 05:09 PM
Longsworth Todd ChristopherGeneral CounselFeb 22Option Exercise21.5521,667466,92426,665Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 22Option Exercise21.5531,201672,382105,288Feb 26 05:13 PM
Danziger AsafChief Executive OfficerFeb 22Option Exercise21.5553,3341,149,348410,124Feb 26 05:11 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 22Option Exercise21.5543,334933,848252,412Feb 26 05:09 PM
Kirson Eilon D.Chief Science OfficerFeb 22Option Exercise21.5536,401784,44239,582Feb 26 05:10 PM
Ambrogi Michael J.Chief Operating OfficerFeb 06Option Exercise0.2350,00011,50074,087Feb 08 04:14 PM
Longsworth Todd ChristopherGeneral CounselJan 29Option Exercise6.7211,63078,15416,628Jan 31 04:29 PM
Longsworth Todd ChristopherGeneral CounselJan 29Sale24.0011,630279,1204,998Jan 31 04:29 PM
Danziger AsafChief Executive OfficerJan 29Sale24.0213,974335,588356,790Jan 31 04:22 PM
Danziger AsafChief Executive OfficerJan 25Sale22.436,456144,840370,764Jan 26 04:14 PM
Danziger AsafChief Executive OfficerJan 24Sale22.1710,600235,007377,220Jan 25 04:26 PM
Danziger AsafChief Executive OfficerJan 23Sale22.0310,248225,794387,820Jan 25 04:26 PM
DOYLE WILLIAM FExecutive ChairmanJan 22Option Exercise3.591,5495,56192,746Jan 24 04:18 PM